COMP <GO>
AVBP vs HELP // EV/EBITDA & P/E VALUATION
ArriVent BioPharma Inc. (NASDAQ) VS. Helus Pharma Inc. (NASDAQ) • 15-METRIC TALLY: AVBP 1
— HELP 1
■ METRIC PARITY
LAST: $15.95 (+1.40%) • MKT CAP: $786.5M
valuation
—
LAST: $10.71 (-1.83%) • MKT CAP: $782.5M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AVBP VS. HELP)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | AVBP | HELP | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | — | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -20.42% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | — | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 32.1 | 44.7 | -12.57 | HELP | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $786.5M | $782.5M | $4.0M | AVBP | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | AVBP REV | HELP REV | AVBP GROSS % | HELP GROSS % | AVBP FCF | HELP FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | — | — | — | -$160.6M | — |
| FY 2024 | $0 | — | — | — | -$70.2M | — |
| FY 2023 | $0 | — | — | — | -$55.8M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AVBP // BETA —
HELP // BETA —